AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/18/21

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10 th Annual Global Healthcare Conference on Thursday, February 25, 202...

On January 22, the FDA approved Voclosporin to treat Lupus Nephritis. A label was included with a personal dosage protocol, which implies that VC will be protected against generics until 2037. VC is expected to generate between $1B and $2B per year. Aurinia is going to be a pr...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and year end 2020 financial results on Wednesday, February 24, 2021, after the markets close. Aurinia’s management team will host a confere...

Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...

Lupkynis is the first FDA-approved oral therapy for lupus nephritis. Approved label supports patented dosing protocol, which will last until 2037. 65k annual revenue is expected per lupus nephritis patient. ~10% lupus nephritis market penetration in five years will give Aurini...

In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications. I then consider more factors in the comparison to competitor drug Benlysta. Finally, I build and justify a DCF model which yields a new price target of $64.25 ...

After nearly two and a half decades, Aurinia Pharmaceuticals' immunosuppressant voclosporin finally garnered FDA approval last week. After flunking a Phase 2/3 dry eye syndrome trial in October 2020, voclosporin for lupus nephritis (LN) is the only meaningful asset/indication for the ...

Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for ...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) recently jumped thanks to excitement about the company's new lupus treatment. The Food and Drug Administration recently made voclosporin (brand name Lupkynis) the company's first commercial-stage product. Analysts who follow Aurin...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , a mid-cap biotech company, closed trading Monday up by a healthy 26%. The stock raced higher in response to the FDA's approval of the company's oral lupus nephritis drug, Lupkynis (aka voclosporin). Lupkynis is indicated for pat...